DSpace-CRIS

Now showing 1 - 5 of 5

Some of the metrics are blocked by your
consent settings
Nasal Cavity and Paranasal Sinus Cancer: Diagnosis and Treatment
(Springer Science and Business Media LLC, 2024-06-27)
Jakimovska, Frodita
;
;
The purpose of this review is to analyze the diagnosis and treatments of the sinonasal malignant tumors throw systematic reviewed literature. The systematic review of the literature was performed according to PRISMA guidelines.
Some of the metrics are blocked by your
consent settings
Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
(Thieme, 2017)
Tafur AJ,
;
Caprini JA,
;
Cote L
;
Trujillo-Santos J
;
Del Toro J,
Even though the Khorana risk score (KRS) has been validated to predict against the development of VTE among patients with cancer, it has a low positive predictive value. It is also unknown whether the score predicts outcomes in patients with cancer with established VTE. We selected a cohort of patients with active cancer from the RIETE (Registro Informatizado Enfermedad TromboEmbolica) registry to assess the prognostic value of the KRS at inception in predicting the likelihood of VTE recurrences, major bleeding and mortality during the course of anticoagulant therapy. We analysed 7948 consecutive patients with cancer-associated VTE. Of these, 2253 (28 %) scored 0 points, 4550 (57 %) 1-2 points and 1145 (14 %) scored ≥3 points. During the course of anticoagulation, amongst patient with low, moderate and high risk KRS, the rate of VTE recurrences was of 6.21 (95 %CI: 4.99-7.63), 11.2 (95 %CI: 9.91-12.7) and 19.4 (95 %CI: 15.4-24.1) events per 100 patient-years; the rate of major bleeding of 5.24 (95 %CI: 4.13-6.56), 10.3 (95 %CI: 9.02-11.7) and 19.4 (95 %CI: 15.4-24.1) bleeds per 100 patient-years and the mortality rate of 25.3 (95 %CI: 22.8-28.0), 58.5 (95 %CI: 55.5-61.7) and 120 (95 %CI: 110-131) deaths per 100 patient-years, respectively. The C-statistic was 0.53 (0.50-0.56) for recurrent VTE, 0.56 (95 %CI: 0.54-0.59) for major bleeding and 0.54 (95 %CI: 0.52-0.56) for death. In conclusion, most VTEs occur in patients with low or moderate risk scores. The KRS did not accurately predict VTE recurrence, major bleeding, or mortality among patients with cancer-associated thrombosis.
Some of the metrics are blocked by your
consent settings
RADIATION-INDUCED MUCOSITIS IN PATIENTS WITH OROPHARINGEAL CANCER TREATED WITH MODERATE ACCELERATION OF INTENSITY-MODULATED RADIATION THERAPY AND SIMULTANEOUS INTEGRATED BOOST CONCOMITANT WITH WEEKLY CISPLATIN
(Scientific foundation Spiroski, 2021)
Kostadinova, Lenche
;
;
;
;
Stoleska Marina
Radiation-induced mucositis is one of the limiting factors during radiotherapy, disturbing the quality of life and in some cases leading to discontinuation of therapy. Intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) represents advanced form of radiotherapy technique in treatment of oropharyngeal carcinoma enabling precision cancer targeting with reducing dose to healthy normal tissues.
Some of the metrics are blocked by your
consent settings
Colon Screening: Colonoscopy vs Virtual Colonoscopy
(2013-03)
;
;
K. Nikolov
Virtual colonoscopy or appropriately named CT Colonography(CTC) is a new radiologic method of screening the colon for precancerous polyps with an ongoing tendention to supplement the regular endoscopic colonoscopy. We are trying to show how this method with the abbility to reconstruct and render the images can better depict the colon and any suspicious lesion thus avoiding the invasivness of the old method and sedation of the patient. We suggest this method for any patient with: * known familial polyposis * blood in the stool * with known Ulcerative colitis or Crohn's disease.
Some of the metrics are blocked by your
consent settings
Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism
(Elsevier, 2018-04)
Chai-Adisaksopha C
;
Iorio A
;
Crowther MA
;
de Miguel J
;
Salgado E
Background: Low-molecular-weight heparin (LMWH) is the treatment of choice in cancer patients with venous thromboembolism. However, data on continuing LMWH treatment beyond 6 months remain scanty. Methods: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to compare the rate of venous thromboembolism recurrences and major bleeding appearing beyond the first 6 months of anticoagulant therapy in cancer patients with venous thromboembolism, according to therapy with LMWH or vitamin K antagonists (VKA). We performed a propensity score-matched cohort study. Results: After propensity matching, 482 cancer patients continued to receive LMWH and 482 switched to VKA. During the course of anticoagulant therapy (mean 275.5 days), 57 patients developed venous thrombosis recurrences (recurrent pulmonary embolism 26, recurrent deep vein thrombosis 29, both 2), 28 had major bleeding, 38 had nonmajor bleeding, and 129 died. No patient died of recurrent venous thrombosis, and 5 patients died of bleeding (2 were on LMWH, 3 on VKA). Patients who continued with LMWH had a similar rate of deep vein thrombosis recurrences (relative risk [RR] 1.41; 95% confidence interval [CI], 0.68-2.93), pulmonary embolism recurrences (RR 0.73; 95% CI, 0.34-1.58), major bleeding (RR 0.96; 95% CI, 0.51-1.79), or nonmajor bleeding (RR 1.15; 95% CI, 0.55-2.40), compared with those who switched to VKA, but a higher mortality rate (RR 1.58; 95% CI, 1.13-2.20). Conclusions: In cancer patients with venous thromboembolism who completed 6 months of LMWH therapy, switching to VKA was associated with a similar risk of venous thrombosis recurrences or bleeding when compared with patients who continued LMWH.

Faculty of Medicine

Browse

Filters

Settings

Sort By

Results per page

Search Results